(Q40694367)

22 September 2017

1 reference

title

Pharmacodynamics and long-term toxicity of etoposide (English)

1 reference

22 September 2017

1 reference

2

Ratain MJ

1 reference

22 September 2017

Kobayashi K

1

1 reference

22 September 2017

publication date

1 January 1994

1 reference

Cancer Chemotherapy and Pharmacology

22 September 2017

published in

1 reference

22 September 2017

volume

34 Suppl

1 reference

22 September 2017

page(s)

S64-8

1 reference

A possible specific chromosome marker for monocytic leukemia: three more patients with t(9;11)(p22;q24) and another with t(11;17)(q24;q21), each with acute monoblastic leukemia

22 September 2017

cites work

1 reference

12 December 2020

Translocation t(9;11)(p21;q23) with acute myelomonocytic leukemia after chemotherapy for osteosarcoma: good response to antileukemic drugs

1 reference

12 December 2020

Secondary leukaemias after epipodophyllotoxins

1 reference

12 December 2020

Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580).

1 reference

12 December 2020

Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity

1 reference

12 December 2020

Correlations between sister chromatid exchange frequencies and replicon sizes. A model for the mechanism of SCE production.

1 reference

12 December 2020

Etoposide. Current and future status

1 reference

12 December 2020

Epipodophyllotoxin-related leukemia. Identification of a new subset of secondary leukemia

1 reference

12 December 2020

Serial measurement of sister chromatid exchanges in the peripheral lymphocytes of patients with lung cancer receiving chemotherapy in relation to bone marrow toxicity

1 reference

12 December 2020

Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide

1 reference

12 December 2020

Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II

1 reference

12 December 2020

Cytogenetic effects of etoposide (VP-16) on human lymphocytes; with special reference to the relation between sister chromatid exchange and chromatid breakage

1 reference

12 December 2020

A limited sampling method for estimation of the etoposide area under the curve

1 reference

12 December 2020

Pharmacodynamics in cancer therapy

1 reference

12 December 2020

Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability.

1 reference

12 December 2020

Acute Nonlymphocytic Leukemia in Germ Cell Tumor Patients Treated With Etoposide-Containing Chemotherapy

1 reference

12 December 2020

Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer

1 reference

12 December 2020

Prospective evaluation of a model for predicting etoposide plasma protein binding in cancer patients.

1 reference

12 December 2020

Secondary acute myeloid leukemia in Hispanic children

1 reference

12 December 2020

The epipodophyllotoxins: both sides of the coin

1 reference

12 December 2020

Myeloid neoplasia in children treated for solid tumours

1 reference

12 December 2020

Anticancer drug pharmacodynamics

1 reference

12 December 2020

Secondary acute lymphoblastic leukemia with t (4;11): report on two cases and review of the literature

1 reference

12 December 2020

Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancer

1 reference

12 December 2020

Secondary neoplasms following treatment of malignant germ cell tumors

1 reference

12 December 2020

Modeling interpatient pharmacodynamic variability of etoposide.

1 reference

12 December 2020

Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia

1 reference

12 December 2020

Acute myeloid leukemia after single-agent treatment with etoposide for Langerhans' cell histiocytosis of bone

1 reference

12 December 2020

Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia

1 reference

12 December 2020

Secondary leukaemias after etoposide

1 reference

12 December 2020

Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation

1 reference

12 December 2020

Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours

1 reference

12 December 2020

1 reference

12 December 2020

Chromosome aberrations induced by etoposide (VP-16) are not random

1 reference

12 December 2020

Clinical pharmacodynamics of continuous-infusion etoposide

1 reference

12 December 2020

Translocation (9;11)(p21;q23) in a child with acute monoblastic leukemia following 2 1/2 years after successful chemotherapy for neuroblastoma

1 reference

12 December 2020

Common region of ALL-1 gene disrupted in epipodophyllotoxin-related secondary acute myeloid leukemia.

1 reference

12 December 2020

High frequency of etoposide (VP-16)-related secondary leukemia in children with non-Hodgkin's lymphoma

1 reference

12 December 2020

Altered protein binding of etoposide in patients with cancer

1 reference

12 December 2020

Relation of systemic exposure to unbound etoposide and hematologic toxicity

1 reference

12 December 2020

Increased frequency of chromosomal damage in peripheral blood lymphocytes up to nine years following curative chemotherapy of patients with testicular carcinoma

1 reference

12 December 2020

Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: a phase II study from the Société Française d'Oncologie Pédiatrique

1 reference

12 December 2020

Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function

1 reference

12 December 2020

Secondary Leukemia Associated With a Conventional Dose of Etoposide: Review of Serial Germ Cell Tumor Protocols

1 reference

12 December 2020

Cytogenetic effects of multiagent chemotherapy on the peripheral lymphocytes of patients with small cell lung cancer

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer

1 reference

12 December 2020

Report of the Cancer Therapy Evaluation Program monitoring plan for secondary acute myeloid leukemia following treatment with epipodophyllotoxins

1 reference

12 December 2020

Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7

1 reference

12 December 2020

Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00684866

1 reference

Dimensions Publication ID

22 September 2017

1007248640

0 references

1 reference